Refractory Hodgkin Lymphoma (DBCOND0029144)

Identifiers

Synonyms

Refractory Hodgkin's lymphoma / Hodgkin Disease Refractory / Hodgkin's disease refractory / Refractory Hodgkin Disease / Refractory Hodgkin's disease / Refractory Hodgkin lymphoma / Refractory Hodgkin lymphoma (disorder) / Hodgkin's disease NOS refractory

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Bendamustine	An antineoplastic nitrogen mustard agent used in the treatment of indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed following rituximab therapy.	Cytochrome P450 1A2enzyme
Carboplatin	A alkylating agent used to treat advanced ovarian cancer.	DNAtarget High affinity copper uptake protein 1transporter Protein SLC31A2transporter Xanthine dehydrogenase/oxidaseenzyme Myeloperoxidaseenzyme Glutathione S-transferase theta-1enzyme Metallothionein-1Aenzyme Metallothionein-2enzyme Superoxide dismutase [Cu-Zn]enzyme Glutathione S-transferase Penzyme Glutathione S-transferase Mu 1enzyme NAD(P)H dehydrogenase [quinone] 1enzyme Copper-transporting ATPase 1transporter Copper-transporting ATPase 2transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-binding cassette sub-family C member 2transporter
Carmustine	An alkylating agent used in the treatment of various malignancies, including brain tumours and multiple myeloma, among others.	Glutathione reductase, mitochondrialtarget DNAtarget RNAtarget
Lomustine	An alkylating agent used as a part of chemotherapeutic regimens for the treatment of primary and metastatic brain tumors as well as refractory or relapsed Hodgkin's disease in addition to surgical and/or radiotherapeutic treatments.	DNAtarget Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme Stathmin-4target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04268706	Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)	Bendamustine Fludarabine	treatment	2	active_not_recruiting
NCT05352828	Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy	No drug interventions	treatment	1	active_not_recruiting
NCT03259503	Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant	No drug interventions	treatment	1	active_not_recruiting
NCT04640779	Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma	No drug interventions	treatment	1	recruiting
NCT01921387	Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies	Beta-D-Glucose Carmustine Cytarabine Etoposide Mechlorethamine	treatment	1 / 2	completed
NCT03013933	Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	Brentuximab vedotin Cyclosporine Verapamil	treatment	1	completed
NCT05595447	Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma	Brentuximab vedotin Nivolumab Pembrolizumab	treatment	2 / 3	recruiting
NCT04681105	Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	Acetaminophen Dexamethasone Diphenhydramine Flotetuzumab Ibuprofen Ranitidine	treatment	1	active_not_recruiting
NCT04052997	Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma	Camidanlumab tesirine	treatment	2	completed
NCT01619761	NK Cells in Cord Blood Transplantation	Cyclophosphamide Fludarabine Lenalidomide Mechlorethamine Mycophenolate mofetil Natural Killer Cell Rituximab Tacrolimus	treatment	1	unknown_status
NCT00860171	Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	No drug interventions	treatment	1	terminated
NCT02181478	Intra-Osseous Co-Transplant of UCB and hMSC	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	0	completed
NCT04871607	Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma	Basiliximab Beta-D-Glucose Carmustine Cytarabine Etoposide Filgrastim Yttrium Y-90	treatment	2	recruiting
NCT02456675	INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma	Dezapelisib Itacitinib	treatment	2	terminated
NCT02227199	Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	Beta-D-Glucose Brentuximab vedotin Carboplatin Cyclophosphamide Etoposide Ifosfamide	treatment	1 / 2	active_not_recruiting
NCT00723099	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	No drug interventions	treatment	2	completed
NCT03432741	Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer	Belinostat Carfilzomib Copanlisib Daratumumab Fludeoxyglucose (18F) Fluorine F-18 Gemcitabine Nivolumab Obinutuzumab Pembrolizumab Rituximab Romidepsin Trastuzumab	treatment	1	suspended
NCT02304458	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas	Ipilimumab Nivolumab	treatment	1 / 2	completed
NCT03730363	Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma	Pentamidine	treatment	1	completed
NCT01701986	Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma	Aloe vera leaf Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Ascorbic acid Busulfan Clofarabine Clofarabine Gemcitabine Glycerin Mycophenolate mofetil Nicotinamide Rituximab Tacrolimus Vitamin A	treatment	1 / 2	completed
NCT02254239	Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	Brentuximab vedotin Everolimus	treatment	1	terminated
NCT04134325	Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma	Nivolumab Pembrolizumab	treatment	0	recruiting
NCT04776265	RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT	No drug interventions	Not Available	Not Available	recruiting
NCT03213665	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Tazemetostat	treatment	2	active_not_recruiting
NCT06484920	A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL	Pembrolizumab Tretinoin	treatment	2	recruiting
NCT00789776	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	No drug interventions	treatment	1 / 2	completed
NCT02744612	Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	No drug interventions	treatment	2	active_not_recruiting
NCT01231412	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	No drug interventions	treatment	3	completed
NCT03057795	Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma	No drug interventions	treatment	2	active_not_recruiting
NCT00005803	Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	Beta-D-Glucose Carmustine Cyclophosphamide Cyclosporine Cytarabine Etoposide Fludarabine Mechlorethamine Mycophenolate mofetil	treatment	1 / 2	completed
NCT05272384	Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma	No drug interventions	treatment	1	recruiting
NCT02869633	Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	No drug interventions	treatment	2	completed
NCT03016871	Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL	No drug interventions	treatment	2	active_not_recruiting
NCT00075478	Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	3	completed
NCT04938232	Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL	No drug interventions	treatment	2	active_not_recruiting
NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	No drug interventions	treatment	2	withdrawn
NCT01703949	Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma	No drug interventions	treatment	2	recruiting
NCT03739619	Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	No drug interventions	treatment	1 / 2	active_not_recruiting
NCT01393717	Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma	No drug interventions	treatment	2	completed
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	No drug interventions	treatment	1	terminated
NCT06487624	An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors	No drug interventions	treatment	1	not_yet_recruiting
NCT05137886	PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma	No drug interventions	treatment	2	recruiting
NCT02824029	Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	No drug interventions	treatment	2	active_not_recruiting
NCT01897012	Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	No drug interventions	treatment	1	completed